It is a very interesting and impactful research protocol for a better monitoring and management of acute kidney transplant rejection. It is feasible, given the numbers of centres participating and the expertise of the involved investigators; and importantly, generalisable. The novelty of the protocol relies on the incorporation of biomarker-driven surveillance biopsies in a clinical trial in a subpopulation of patients with greater immune risk as defined by the class II HLA mismatches (the intervention group); thus, likely to benefit from it and to contribute with higher yield results. In addition, they incorporate in their protocol the acquisition of a biobank as a legacy for future investigations. All these aspects of their protocol are in tune with some recommendations we published in an editorial in Dec 2017 (PMID: 29312857). Therefore, I have no major concern in their design or strength of their hypothesis, and I trust the research funds will be well-utilised, and I am looking forward to their results. In addition, their statistical methods are adequate, and the unavoidable limitation of lack of masking is commented.
However, I would like to request the investigators to please clarify what the conventional monitoring protocol will consist of. It has been difficult to find the best possible transplant control population for different protocols. At first glance, it might seem appropriate to compare their intervention (a biomarker-driven biopsy) with conventional monitoring. However, taking into account that the starting population in both arms is at higher risk for rejection in accordance to both class II HLA mismatches and positivity for their biomarker (which is by itself one of the strengths of their protocol), makes me wonder if the conventional monitoring could be the best control or not. Could be then perhaps/instead a monitoring approach based on protocolised surveillance biopsies (not biomarker-driven) at arbitrary intervals, rather than only a surveillance biopsy at 12 months be a better control-option to the other arm also positive for the biomarker? Something the authors can consider as an option if they think pertinent; or they can please support their choice (in regards to this) with a short statement. Or if the decision is difficult, would it be too cumbersome to consider a three-arm protocol? In which the intervention group could be the biomarker-driven protocol biopsy, and the control groups could be A) the conventional monitoring with a biopsy at 12 months and B) an extra group with protocolised scheduled biopsies according to the time post-transplant eg 1, 3, 6 12 months (or depending on the known timing and incidence of acute rejection within the first year in their population/clinical setting) or whatever schedule the investigators believe as pertinent after testing positive for the biomarker and being included into the protocol. In addition, this could be regarded safer (not missing rejection or immune inflammation); although the invasiveness of more scheduled surveillance biopsies needs to be factored in.
Including that control will contribute with greater and deeper acquisition of histological dynamic data that could be exploited if not by this protocol, in future ones, in tune with their legacy biobank. On the contrary, if the investigators decide that conventional monitoring is the best control after defining it and explaining the pros and cons of it, then I would suggest the incorporation of an interim analysis to be sure no significant cases of rejection or immune-mediated inflammation (in any of its spectrum) are missed by the conventional monitoring, waiting until 12 months.
All the outcomes selected are relevant, but I have a small concern lumping together graft loss with different types of immunemediated inflammation, especially when one is tubulitis, irrespective it could portend bad prognosis, but very dissimilar from graft loss in regards to implications in all aspects for the patient and physicians. Creating a composite outcome will increase the yield of results and aid in statistical analysis, but in that case, the investigators could define that their primary outcome means "any type of immune-mediated inflammation from tubulitis till graft loss" (all its spectrum), rather than implicitly suggesting that tubulitis can be as bad as rejection (the inherent problem of composite outcomes). Alternatively, it can remain as it is: as any type of immune inflammation, but independently graft loss could be assessed separately as a primary or a secondary outcome. Given the protocol and time period studied, indeed reduction in ongoing immune-mediated inflammation should be the expectation from the protocol, and might not have too many expected cases of immune-mediated graft loss as they will be discovering subclinical rejection timely and treating it appropriately and opportunely.
I would like to ask the investigators what would be their approach if an increment in creatinine is detected in their recruited patients? Would they test for their biomarker and then if positive do a biopsy? Would they do a biopsy only if no other causes are identified but they will not test for the biomarker-or test for their records only, but not to base their clinical decision on finding or not positive biomarker after a rise in creatinine? Because another way to utilise their biomarker beyond their protocol is for those cases of unexplained increment in serum creatinine…it might be expected that both, a rise in creatinine taken together with a positive biomarker, will increase the yield for finding rejection and then help to expedite a confirmatory kidney biopsy.
Finally, although the protocol is clear, perhaps rephrasing their primary hypothesis statement could be ideal, as it gives the impression that the trigger for treatment is the positivity of their biomarker alone, rather than the biomarker is both a requirement for inclusion and monitoring, and a trigger for a surveillance biopsy, and then if rejection is found on that biopsy, that is, in fact, the trigger for treatment. In this respect, any benefit in adding to the title the word biopsy?
Overall, it is a great protocol and I definitively support it and looking forward to their eventual results. The investigators could take into consideration the points exposed above and do modifications if they deem pertinent. Otherwise, just clarify it, please. Thank you and best of lucks. 2. In Abstract and in many places in the manuscript, the authors use the abbreviation "EQ-5DL" without spelling it out at first use. I could not find that exact term in my searches. The commonly used EuroQol five dimension (5D) instrument to assess health status has several subvariants, such as EQ-5D-3L (three levels) or EQ-5D-5L (five levels). There does not appear to be any EQ-5DL instrument. Please clarify and spell out exactly. 3. In the protocol, the authors explain acute rejection, immunosuppression and alloimmune monitoring in great detail, but have not provided any details on anti-infective prophylaxis or any viral monitoring, both as equally important as the other described protocol aspects in kidney transplantation. Is there no protocol for anti-infective prophylaxis, i.e., no data elements will be collected? Or is it entirely per center discretion, and you will collect these data elements? 4. IV Thymoglobulin (a brand name, better expressed as rabbit anti-thymocyte globulin) dosing is listed 3-6 mg/kg, without specifying how many mg/kg each dose might be (typically the dose range is anywhere from 0.5 to 1.5 mg/kg, then number of doses is also specified, thus determining total dose). 5. Long-term outcomes will be assessed by administrative database linkages per the authors -how exactly? To my knowledge, there is no field in current administrative databases to record a study name or study subject ID number, for deterministic matching. I presume the authors plan for probabilistic matching based on age, race and gender, which has many limitations. Please specify what you plan to do. 6. In many places, the authors refer to a change from implantation biopsy to required 12 month study exit biopsy (in the three centers that perform surveillance biopsies), but an implantation biopsy is not mentioned at all in the schedule of events or main text protocol design. Are all 3 study centers that perform surveillance biopsies also routinely performing an implantation biopsy? This is not the routine clinical practice at most centers worldwide. If yes, then why are you performing implantation biopsies? The reason they are not used is because they provide no evidence-based benefit, and may cause harm. 7. The authors mention multivariate modeling but have not listed pre-hoc which covariates they plan to include. With both induction immunosuppression and maintenance steroids being at the discretion of the treating physician (not even the center), the variability in subjects is going to be very high. Listing all covariates pre-hoc is desirable. 8. Medication adherence is being measured by just one parameter, the adequacy of tacrolimus trough levels. Multiple studies have shown that valid medication adherence measurement needs assessment of multiple adherence parameters, of which adequacy of levels is NOT considered to be a sufficient measure (whereas coefficient of variation in tacrolimus trough levels is). Will the study also incorporate pharmacy refill records or pill counts? 9. The criteria for high immunological risk is define by HLA mismatch, eplet mismatch, PRA > 95% or prior kidney transplant. What about the impact of African ancestry (or black race) donor or recipient? The impact of delayed graft function? These are also commonly used at many centers to also define higher immunological risk. Given the location of the 6 study centers in Canada and Australia, it is likely that African ancestry recipients will be minimal among the study population, and may limit the generalizability of the study results.
REVIEWER

VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
The investigators have submitted a well-written protocol, which is also well-referenced.
Thank you for the comments and detailed review.
However, I would like to request the investigators to please clarify what the conventional monitoring protocol will consist of. It has been difficult to find the best possible transplant control population for different protocols. At first glance, it might seem appropriate to compare their intervention (a biomarker-driven biopsy) with conventional monitoring. However, taking into account that the starting population in both arms is at higher risk for rejection in accordance to both class II HLA mismatches and positivity for their biomarker (which is by itself one of the strengths of their protocol), makes me wonder if the conventional monitoring could be the best control or not. Could be then perhaps/instead a monitoring approach based on protocolised surveillance biopsies (not biomarker-driven) at arbitrary intervals, rather than only a surveillance biopsy at 12 months be a better control-option to the other arm also positive for the biomarker? Something the authors can consider as an option if they think pertinent; or they can please support their choice (in regards to this) with a short statement.
Or if the decision is difficult, would it be too cumbersome to consider a three-arm protocol? In which the intervention group could be the biomarker-driven protocol biopsy, and the control groups could be A) the conventional monitoring with a biopsy at 12 months and B) an extra group with protocolised scheduled biopsies according to the time post-transplant eg 1, 3, 6 12 months (or depending on the known timing and incidence of acute rejection within the first year in their population/clinical setting) or whatever schedule the investigators believe as pertinent after testing positive for the biomarker and being included into the protocol. In addition, this could be regarded safer (not missing rejection or immune inflammation); although the invasiveness of more scheduled surveillance biopsies needs to be factored in. Including that control will contribute with greater and deeper acquisition of histological dynamic data that could be exploited if not by this protocol, in future ones, in tune with their legacy biobank.
Thank you for the very thoughtful question. We debated this issue extensively during the trial design phase, as our lead site is a protocol biopsy center as well as some of our participating centers. Ultimately, we chose not to perform protocol biopsies in the Control Arm as it is not reflective of standard-of-care monitoring for most transplant centers in Canada and elsewhere. A recent survey by Hariharan et al. indicates that only 38% US centers perform protocol biopsies, 17% routinely and 21% in selected cases only (1) , and this distribution is similar in Europe. As the Control Arm should reflect standard-of-care practices, the conventional monitoring protocol only includes monitoring of graft function (serum creatinine, proteinuria), but not graft histology. We anticipate that this standard-ofcare Control comparison will help enable downstream uptake of the trial findings and improve the overall generalizability of the results to all transplant centers, instead of the one-third of centers that perform protocol biopsies.
On the contrary, if the investigators decide that conventional monitoring is the best control after defining it and explaining the pros and cons of it, then I would suggest the incorporation of an interim analysis to be sure no significant cases of rejection or immune-mediated inflammation (in any of its spectrum) are missed by the conventional monitoring, waiting until 12 months.
Thank you for the comments. We designed and powered this clinical trial without a planned interim analysis. The rationale is that a planned interim analysis would significantly increase our required sample size and target population to be enrolled, which may limit the overall trial feasibility.
This trial will be monitored by an independent Data Safety Monitoring Board (DSMB) provided through the Canadian Donation and Transplant Research Program (CDTRP). Ongoing safety monitoring will be performed to ensure there is no evidence of over-whelming harm that would require stopping the trial prematurely. We will specifically monitor if there are significantly increased rates of clinical biopsyproven rejection in the Control vs. Intervention Arms.
All the outcomes selected are relevant, but I have a small concern lumping together graft loss with different types of immune-mediated inflammation, especially when one is tubulitis, irrespective it could portend bad prognosis, but very dissimilar from graft loss in regards to implications in all aspects for the patient and physicians. Creating a composite outcome will increase the yield of results and aid in statistical analysis, but in that case, the investigators could define that their primary outcome means "any type of immune-mediated inflammation from tubulitis till graft loss" (all its spectrum), rather than implicitly suggesting that tubulitis can be as bad as rejection (the inherent problem of composite outcomes). Alternatively, it can remain as it is: as any type of immune inflammation, but independently graft loss could be assessed separately as a primary or a secondary outcome. Given the protocol and time period studied, indeed reduction in ongoing immune-mediated inflammation should be the expectation from the protocol, and might not have too many expected cases of immune-mediated graft loss as they will be discovering subclinical rejection timely and treating it appropriately and opportunely.
Thank you. We extensively debated the primary composite outcome during the trial design phase. One of the major barriers in conducting transplant trials is that the only FDA-accepted outcomes are graft loss, clinical biopsy-proven acute rejection and death; but these are no longer sufficient to assess interventions aimed at improving long-term graft survival in this era of modern immunosuppression (2-5). The event rates of graft loss and clinical biopsy-proven acute rejection are very low in the first year post-transplant, thereby limiting trial feasibility (re: power, recruitment). This limitation has been well-recognized by the transplantation community, and discussions through the TTS and FDA are ongoing to define acceptable surrogate outcomes for graft loss to use in transplant trials (6).
The primary composite endpoint was developed using the following guiding principles whereby all components of the final composite endpoint must be: 1. FDA-approved or highlighted as plausible surrogates at the TTS-FDA meetings. 2. Follow alloimmune-mediated causal pathways linked to allograft loss so the effect on the composite endpoint is reasonably likely to predict clinical benefit. 3. Independently contribute to graft loss. 4. May be positively impacted by the early detection and treatment of alloimmune-mediated inflammation. 5. Be robust enough to potentially qualify for "accelerated approval (subpart H)" by the FDA. 6. Together be of sufficient frequency so as to allow for a feasible sample size for a short-term study up to 12-months post-transplant.
Each component of the primary composite outcome was selected for the following reasons:
1. Death-censored graft loss defined by the return to dialysis or re-transplantation is an FDA-approved outcome.
2. Biopsy-proven clinical acute rejection defined by Banff criteria is an FDA-approved outcome (7-9). 3. De novo donor specific antibody (dnDSA) at 12-months detected by solid-phase immunoassays.
De novo donor specific antibody is a major risk factor for graft loss (10) (11) (12) and under consideration by the TTS-FDA as a surrogate marker. 4 . Inflammation in areas of atrophy at 12-months (i-IFTA) defined by Banff 2017 (13) . Interstitial fibrosis and tubular atrophy (IFTA) accompanied by low-grade interstitial inflammation in atrophic (DeKAF iatr, Banff 2017 i-IFTA) and non-atrophic areas (IFTA+i, Mayo criteria) (14-18) is associated with poor long-term graft outcomes (19) (20) (21) . These entities are associated with previous acute rejection episodes (20, 21) ; increased HLA mismatch (14, 16); rejection-like gene signatures (15, 22) ; and graft loss (14, 17, 19, (21) (22) (23) (24) . A seminal study evaluating sequential histology showed i-IFTA is preceded by early TCMR/vascular rejection events, and followed by transition to i-IFTA versus pure IFTA which has better long-term outcomes (20 (24, 26) . As this criterion is defined by Banff t-score, it will capture any type of immune-mediated inflammation leading to tubulitis.
We have now included the rationale for the different components of the primary outcome in the revised manuscript.
All clinical indication biopsies are at the discretion of the treating physician, whether it be for an increment in serum creatinine or proteinuria. Urine samples will be collected at the time of each clinical indication biopsy and tested for urine CXCL10, for observational purposes only and CXCL10 will not be used to direct the care of clinically indicated biopsies.
We agree that urine CXCL10 may rise in advance of serum creatinine in early clinical rejection, and not just with subclinical rejection according to the data by Matz et al. and the CTOT-01 study (27, 28) . Therefore serial urine CXCL10 data will be analyzed over time to delineate the kinetics of urine CXCL10 rise prior to biopsy-proven rejection and in response to therapy (bi-weekly urines collected for 4 weeks after rejection treatment initiated). These data may help increase the yield of positive urine CXCL10 in detecting rejection on a confirmatory kidney biopsy.
Thank you for the suggestion. We have modified the primary hypothesis statement accordingly in the revised manuscript, to include the biopsy confirmation.
Overall, it is a great protocol and I definitively support it and looking forward to their eventual results. The investigators could take into consideration the points exposed above and do modifications if they deem pertinent. Otherwise, just clarify it, please. Thank you and best of lucks.
Thank you for the detailed review.
Reviewer 2 There is a clear indication for the study. Could the authors please address the following? 1) On Page 11 Ln 12, the differing induction immunosuppression and maintenance steroids used by the six centres be defined.
There is significant center-to-center variation in the use of induction therapy and steroid tapering protocols in the early post-transplant period. The protocol mandates triple maintenance immunosuppression, however this protocol does not begin until 2-weeks post-transplant so we did not standardize the induction immunosuppression and steroid taper. Therefore, data on the differing induction immunosuppression and steroid regimens will be collected on each participant and reported in the final study cohort. Finally, in order to account for center-specific differences in induction therapy and steroid protocols, the randomization is stratified by center.
2) On Page 11 Ln 26, could the authors expand on duration of CMV prophylaxis used?
CMV prophylaxis will be performed according to the 2018 International Consensus Guidelines on the Management of CMV in solid organ transplantation (29), and we have clarified this in the revised manuscript. Data will be collected on CMV prophylaxis, viremia and events.
3) Please expand why or how the primary composite endpoints were chosen.
Thank you for the question. Please see our response to this question from Reviewer 1 and we have included the rationale for the primary composite endpoint in the revised manuscript.
4) Please expand on why the QoL score was used -is this to judge the burden of biopsy protocol used compared to just measuring urine CXCL10?
Thank you. This will be used to judge the burden of implementing a urine CXCL10 monitoring strategy in incident renal transplant patients, and it will also be used as a component of the cost-effectiveness analysis.
5) Page 7, please highlight the other potential causes of raised urinary CXCL10 beyond rejection, subclinical TCMR peritubular capillaritis and IFTA.
Urine CXCL10 is elevated when there is graft inflammation of the tubulointerstitial compartment, irrespective of whether it is alloimmune-mediated inflammation. Urine CXCL10 is elevated in T-cell mediated rejection, peritubular capillaritis, BKV viremia/nephritis, and urinary tract infections/pyelonephritis (30, 31) . Urine CXCL10 is not elevated in pure vascular lesions, glomerulitis and CMV viremia, which have inflammation outside of the tubulointerstitial compartment (30) . We have included this information in the revised manuscript.
Reviewer 3 1. The authors have provided a detailed description of the preceding and prevailing literature. Many of the methods are provided in detail. The CONSORT table is appropriately filled out.
Thank you.
2. In Abstract and in many places in the manuscript, the authors use the abbreviation "EQ-5DL" without spelling it out at first use. I could not find that exact term in my searches. The commonly used EuroQol five dimension (5D) instrument to assess health status has several subvariants, such as EQ-5D-3L (three levels) or EQ-5D-5L (five levels). There does not appear to be any EQ-5DL instrument. Please clarify and spell out exactly.
We apologize for the error and have clarified this in the revised manuscript. We are using the EuroQol five dimension (5D) -5 level instrument.
3. In the protocol, the authors explain acute rejection, immunosuppression and alloimmune monitoring in great detail, but have not provided any details on anti-infective prophylaxis or any viral monitoring, both as equally important as the other described protocol aspects in kidney transplantation. Is there no protocol for anti-infective prophylaxis, i.e., no data elements will be collected? Or is it entirely per center discretion, and you will collect these data elements?
Thank you. We agree that anti-infective prophylaxis and viral monitoring are key aspects of kidney transplantation management. We standardized the CMV monitoring and prophylaxis according to the 2018 International Consensus Guidelines on the Management of CMV in solid organ transplantation (29) , and have clarified this in the revised manuscript.
During the trial design phase we identified significant center-to-center variation in management of BKV monitoring and therapy. Indeed, there was also significant center-to-center variation in induction therapy; tacrolimus target trough levels; and steroid dosing suggesting a lack of strong randomized controlled trial data to define best practice for many routine kidney transplant practices. As acute rejection therapy, immunosuppression and alloimmune monitoring are foundational to the evaluating the effect of early treatment of rejection (as detected by urine CXCL10 and confirmed by biopsy), it was imperative from a trial integrity perspective that these practices be standardized between participating centers, and we did standardize these practices.
However we also wished to make the trial as pragmatic and "real-life" as possible, in order to improve the trial feasibility at individual transplant centers and to improve the generalizability of the findings. Therefore we did not standardize the practices for BKV monitoring/therapy, but we will collect and analyze this data. We also did not standardize practices for PJP prophylaxis for the same reason.
4. IV Thymoglobulin (a brand name, better expressed as rabbit anti-thymocyte globulin) dosing is listed 3-6 mg/kg, without specifying how many mg/kg each dose might be (typically the dose range is anywhere from 0.5 to 1.5 mg/kg, then number of doses is also specified, thus determining total dose).
We apologize for the confusion. The total dose is 3-6 mg/kg divided over 3-4 days as tolerated for the rabbit anti-thymocyte globulin and we have clarified this in the revised manuscript.
5. Long-term outcomes will be assessed by administrative database linkages per the authors -how exactly? To my knowledge, there is no field in current administrative databases to record a study name or study subject ID number, for deterministic matching. I presume the authors plan for probabilistic matching based on age, race and gender, which has many limitations. Please specify what you plan to do.
Thank you for the question. We agree that there are no fields in current administrative databases to record a study name or study subject ID number. We obtained ethics approval and have specified in the participant consent forms that we will be collecting personal health identifiers for the subsequent administrative database linkages to obtain long-term outcome data. The personal health identifiers we will collect include: Probabilistic matching will be undertaken with increased weight for matching given to the national transplant/organ replacement registry number (CORR, ANZDATA) and provincial/state health card number (OHIP, PHIN) compared to age, sex and date of transplant. We anticipate that linkage error and false-matches will be limited by this approach which focuses on unique personal health identifier numbers. This may result in missed matches that require follow-up with local data linkages using the medical record number (32).
6. In many places, the authors refer to a change from implantation biopsy to required 12 month study exit biopsy (in the three centers that perform surveillance biopsies), but an implantation biopsy is not mentioned at all in the schedule of events or main text protocol design. Are all 3 study centers that perform surveillance biopsies also routinely performing an implantation biopsy? This is not the routine clinical practice at most centers worldwide. If yes, then why are you performing implantation biopsies? The reason they are not used is because they provide no evidence-based benefit, and may cause harm.
Implantation biopsies are performed as standard of care by all 6 participating transplant centers according to Banff (33) . These are back-table biopsies performed after kidney retrieval and prior to implantation. They are routinely used to establish the donor histological baseline and for comparison with subsequent clinical or protocol biopsies. They are scored according to the Banff criteria/recommendations and only very rarely are they used to determine whether or not the retrieved kidney should be discarded (33).
7. The authors mention multivariate modeling but have not listed pre-hoc which covariates they plan to include. With both induction immunosuppression and maintenance steroids being at the discretion of the treating physician (not even the center), the variability in subjects is going to be very high. Listing all covariates pre-hoc is desirable.
Variable follow-up time from randomization to determination of the 12-month primary composite outcome will be included as a covariate in the model. Additional covariates will be selected to account for any imbalances that occur in the groups despite randomization. The covariates that will be considered include: induction immunosuppression; steroid exposure; tacrolimus trough levels; HLA eplet matching and serological matching; panel reactive antibody; previous transplant; recipient sex, age, and race; delayed graft function; donor type, KDPI and LKDPI; and BKV viremia. We have clarified this information in the revised manuscript.
8. Medication adherence is being measured by just one parameter, the adequacy of tacrolimus trough levels. Multiple studies have shown that valid medication adherence measurement needs assessment of multiple adherence parameters, of which adequacy of levels is NOT considered to be a sufficient measure (whereas coefficient of variation in tacrolimus trough levels is). Will the study also incorporate pharmacy refill records or pill counts?
We absolutely agree with the reviewer that tacrolimus trough levels are a crude measure of adherence and the interaction between medication adherence and poor allograft outcomes is wellestablished (12, 34, 35) . In an earlier version of this trial protocol, we included a MEMs cap analyses to provide granular detail on adherence that could be correlated with urine CXCL10 levels and rejection. Unfortunately, in a small observational pilot on adherence at the University of Manitoba we found that many patients failed to bring their MEMs caps back to clinic for data capture and many patients "lost" their MEMS caps, resulting in a high cost for very little analyzable data. Therefore, from a feasibility perspective we chose not to attempt this in the larger trial cohort.
We also wanted to make the trial as pragmatic and feasible as possible, in order to maximize the trial efficiency and to optimize adherence to the study protocol. We will monitor protocol compliance, but we did not include pharmacy refill records or pill count since the intervention is not a drug, but rather a urine CXCL10 monitoring strategy. We anticipate that randomization should balance the Intervention and Control Arms with respect to behavioral aspects, such as medication adherence. In the event that imbalances occur despite randomization, we will account for these in the multivariate modeling (above).
9. The criteria for high immunological risk is define by HLA mismatch, eplet mismatch, PRA > 95% or prior kidney transplant. What about the impact of African ancestry (or black race) donor or recipient?
The impact of delayed graft function? These are also commonly used at many centers to also define higher immunological risk. Given the location of the 6 study centers in Canada and Australia, it is likely that African ancestry recipients will be minimal among the study population, and may limit the generalizability of the study results.
We agree that early ischemia reperfusion injury can expose epitopes for allorecognition and delayed graft function is a risk factor for death-censored graft loss (36) . We revised the manuscript to include that we will adjust for those individuals that develop delayed graft function.
Given the Canadian and Australian populations, we anticipate there will be a very low frequency of African ancestry, which we agree will limit the generalizability of findings. We have included this limitation in the revised manuscript.
